No significant association was found within the Fluorouracil (5FU), Epirubicin and Cyclophosphamide (FEC) and Epirubicin-Cyclofosfamide (EC) schemes as well as no association was found in the group identified by endocrine and anti-HER2 therapies suggesting that miR-210-3p expression may affect the sensitivity of tumours treated with Docetaxel. This evidence concerns the gene ERBB2 and neoplasm.